Literature DB >> 27803739

Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence.

Yuko Akazawa1, Daisuke Fukuda2, Yutaka Fukuda2.   

Abstract

Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, and H. pylori infection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use in H. pylori eradication. The latest literature and our clinical experience have shown that vonoprazan-based therapies have satisfactory eradication rates. Additionally, vonoprazan-based therapies are associated with similar rates of adverse events as standard triple therapies with conventional proton-pump inhibitors.

Entities:  

Keywords:  H. pylori; P-CAB; PPI; TAK-438; Takecab; Vonoprazan; potassium-competitive acid blocker

Year:  2016        PMID： 27803739      PMCID： PMC5076777          DOI： 10.1177/1756283X16668093

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


  44 in total

Review 1.  Novel approaches to the pharmacological blockade of gastric acid secretion.

Authors:  Michael E Parsons; David J Keeling
Journal:  Expert Opin Investig Drugs       Date:  2005-04       Impact factor: 6.206

2.  The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection.

Authors:  P O Erah; A F Goddard; D A Barrett; P N Shaw; R C Spiller
Journal:  J Antimicrob Chemother       Date:  1997-01       Impact factor: 5.790

3.  Interaction of a K(+)-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and dephosphoenzyme forms of H+, K(+)-ATPase.

Authors:  J Mendlein; G Sachs
Journal:  J Biol Chem       Date:  1990-03-25       Impact factor: 5.157

4.  Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).

Authors:  Yasuyoshi Arikawa; Haruyuki Nishida; Osamu Kurasawa; Atsushi Hasuoka; Keizo Hirase; Nobuhiro Inatomi; Yasunobu Hori; Jun Matsukawa; Akio Imanishi; Mitsuyo Kondo; Naoki Tarui; Teruki Hamada; Terufumi Takagi; Toshiyuki Takeuchi; Masahiro Kajino
Journal:  J Med Chem       Date:  2012-04-30       Impact factor: 7.446

5.  Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.

Authors:  Y Sakurai; Y Mori; H Okamoto; A Nishimura; E Komura; T Araki; M Shiramoto
Journal:  Aliment Pharmacol Ther       Date:  2015-07-21       Impact factor: 8.171

6.  The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.

Authors:  Sho Suzuki; Takuji Gotoda; Chika Kusano; Kunio Iwatsuka; Mitsuhiko Moriyama
Journal:  Am J Gastroenterol       Date:  2016-05-17       Impact factor: 10.864

7.  Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients.

Authors:  N Broutet; S Tchamgoué; E Pereira; H Lamouliatte; R Salamon; F Mégraud
Journal:  Aliment Pharmacol Ther       Date:  2003-01       Impact factor: 8.171

8.  Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy.

Authors:  Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Chise Kodaira; Masafumi Nishino; Mutsuhiro Ikuma; Takashi Ishizaki; Akira Hishida
Journal:  Helicobacter       Date:  2007-08       Impact factor: 5.753

9.  The long-term efficacy of Helicobacter pylori eradication therapy in patients with idiopathic thrombocytopenic purpura.

Authors:  Masaaki Satake; Jun Nishikawa; Yuki Fukagawa; Keiko Akashi; Takeshi Okamoto; Tomoharu Yoshida; Atsuyoshi Hirano; Noboru Maetani; Youzou Iida; Isao Sakaida
Journal:  J Gastroenterol Hepatol       Date:  2007-06-07       Impact factor: 4.029

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396
View more
  6 in total

Review 1.  Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea.

Authors:  Jun-Hyung Cho; So-Young Jin
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

2.  Proton pump inhibitors for chronic obstructive pulmonary disease.

Authors:  Shino Kikuchi; Hissei Imai; Yoko Tani; Tomoko Tajiri; Norio Watanabe
Journal:  Cochrane Database Syst Rev       Date:  2020-08-25

Review 3.  Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection.

Authors:  Maria Teresa Mascellino; Barbara Porowska; Massimiliano De Angelis; Alessandra Oliva
Journal:  Drug Des Devel Ther       Date:  2017-07-28       Impact factor: 4.162

4.  Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.

Authors:  Hidetaka Okubo; Junichi Akiyama; Masao Kobayakawa; Megumi Kawazoe; Saori Mishima; Yusuke Takasaki; Naoyoshi Nagata; Takayuki Shimada; Chizu Yokoi; Shiori Komori; Kana Kimura; Yuya Hisada; Eri Iwata; Kazuhiro Watanabe; Naohiro Yanagisawa; Sho Shiroma; Akira Shimomura; Koki Okahara; Hourin Cho; Naomi Uemura
Journal:  J Gastroenterol       Date:  2020-09-15       Impact factor: 7.527

Review 5.  Esophageal manifestation in patients with scleroderma.

Authors:  Theodoros A Voulgaris; Georgios P Karamanolis
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

6.  Correlation Analysis Among Genotype Resistance, Phenotype Resistance, and Eradication Effect After Resistance-Guided Quadruple Therapies in Refractory Helicobacter pylori Infections.

Authors:  Zijun Guo; Shuxin Tian; Weijun Wang; Yanbin Zhang; Jing Li; Rong Lin
Journal:  Front Microbiol       Date:  2022-03-07       Impact factor: 5.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.